Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for AnaptysBio’s Rosnilimab

Leerink Partners analyst David Risinger has maintained their bullish stance on ANAB stock, giving a Buy rating today.

David Risinger has given his Buy rating due to a combination of factors including the promising results from AnaptysBio’s rosnilimab Phase 2b trial in rheumatoid arthritis. The trial demonstrated significant efficacy over 28 weeks in both biologic-naïve and experienced patients, with benefits lasting at least two months after treatment cessation. Additionally, rosnilimab showcased a favorable safety and tolerability profile compared to existing treatments, marked by low discontinuation rates.
Moreover, the drug’s unique mechanism of action, which involves the depletion of pathogenic PD-1+ T cells and the increase of regulatory T cells, contributes to its potential in addressing unmet needs in the difficult-to-treat RA population. The expert rheumatologists involved in the discussion were impressed by the sustained reduction in disease activity and low infection rates, further supporting the drug’s potential. AnaptysBio’s strong financial position, with substantial cash reserves, also supports its continued development and potential market success.